Go ahead for leg wound study

Tripep starts a phase II-study of their wound healing joint venture project.
The Swedish Medical Products Agency has given their approval to a new phase II study of Chronseal, a project for wound healing jointly owned and developed by Swedish Tripep and their japanese partner company Kringle Pharma. The multi-center study will be made in Sweden and Norway, and include 75 patients with chronic leg ulcers. The placebo-controlled study is planned to end at the end of this year.

ChronSeal is a gel containing human hepatopoietin, Hepatocyte Growth Factor, (HGF), which plays a key role in wound healing. The treatment method has been successfully tested on patients with chronic leg ulcers. In an earlier pilot study, 8 out of eleven showed a wound healing 60 to 100 per cent. Estimates say that 4 million people in the US alone suffer from chronic leg ulcers, and there is a large medical need for effective treatments.

Kommentera en artikel
Meddela redaktionen
Se alla medlemsnyheter
Mest läst
Senaste nytt
Se senaste nytt
Utvalda artiklar
Utvalda nyheter från förstasidan
Vicore tar in 200 miljoner — utvecklar behandling mot lungfibros
Stororder till samarbetspartner kan bli bingo för Raysearch
Ny Sverigechef till Boehringer Ingelheim
FDA kräver indraget tillstånd för Oncopeptides i USA
Uppmärksamheten kring ALS ger pengar till hennes forskning
Spago startar klinisk studie i endometrios
Andra Nordiska Medier
MedTech Magazine

Sänd till en kollega